Podcast

Updates in Advanced HER2-Positive Breast Cancer

Author(s):

OncLive Staff

Dr Mahtani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Shipra Gandhi, MD
A panel of 5 experts on breast cancer
A panel of 5 experts on breast cancer
Related Content
Lajos Pusztai, MD, DPhil
July 25th 2024

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center
July 18th 2024

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Priscilla F. McAuliffe, MD, PhD, of UPMC Hillman Cancer Center
July 24th 2024

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, European Institute of Oncology
July 15th 2024

Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

Paolo Tarantino, MD
July 23rd 2024

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer